Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 1, 2013, Pages 57-63

  Kim, Seung Tae ^a   Jung, Hae Yun ^b   Sung, Jae Sook ^b   Jo, Uk Hyun ^b   Tanaka, Tomoaki ^c   Hagiwara, Koichi ^c   Park, Kyong Hwa ^a   Shin, Sang Won ^a   Kim, Jun Suk ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

EGFR mutation; NSCLC; serum and tumor samples

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LOCKED NUCLEIC ACID; PEPTIDE NUCLEIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872913887     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31823a5217     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002
2. CA Cancer J Clin. 2005;55:74-108
3. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47
4. Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol. 2008;134: 569-577 (Pubitemid 351422610)
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98 (Pubitemid 34438899)
6. van Zandwijk N, Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol. 1996;8:120-125 (Pubitemid 26156436)
7. Yuh YJ, Lee HR, Kim SR. Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced non-small cell lung cancer: A feasibility study. Cancer Res Treat. 2008;40:116-120
8. Scott CL, Zalcberg JR, Irving LB. Treatment principles in advanced non-small cell lung cancer. Aust N Z J Surg. 1996;66:688-693 (Pubitemid 26323493)
9. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005; 353:123-132 (Pubitemid 41058344)
11. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246 (Pubitemid 46621858)
12. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA. 2003;290:2149-2158 (Pubitemid 37432975)
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957
14. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081-8092 (Pubitemid 46657411)
15. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909
16. Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant nonsmall cell lung cancers. Lung Cancer. 2007;58:95-103 (Pubitemid 47379970)
17. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67-70 (Pubitemid 29062958)
18. Sanchez-Cespedes M, Monzo M, Rosell R, et al. Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients. Ann Oncol. 1998;9:113-116 (Pubitemid 28125774)
19. Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97:778-784 (Pubitemid 47396294)
20. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276-7282 (Pubitemid 41161259)
21. Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clampbased test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 2007;98:246-252 (Pubitemid 44941878)
22. Miyazawa H, Tanaka T, Nagai Y, et al. Peptide nucleic acidlocked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 2008;99:595-600 (Pubitemid 351228579)
23. Maemondo M, Inoue A, Kobayashi K, et al, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388
24. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small cell lung cancer. J Clin Oncol. 2009;27:2653-2659
25. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 2004;64:8919-8923 (Pubitemid 39665498)
26. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4:22-29
27. Lim KH, Huang MJ, Liu HC, et al. Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol. 2007;24:388-393
28. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small cell lung cancer. Curr Med Res Opin. 2006;22:561-573
29. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res. 2008;14:3860-3866
30. Jang TW, Oak CH, Chang HK, et al. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24:48-54
31. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824 sss (Pubitemid 350002184)